Notice to Long-term Actinium Pharmaceuticals, Inc. (ANTM) Shareholders: Grabar Law Investigates Claims on Your Behalf

Philadelphia, Pennsylvania--(Newsfile Corp. - March 28, 2025) - Grabar Law Office is investigating whether the Board of Directors of Actinium Pharmaceuticals, Inc. (NYSE: ANTM) breached their fiduciary duties owed to the Company.

Current Actinium Pharmaceuticals, Inc. (NYSE: ANTM) shareholders who have held the stock since on or before October 31, 2022, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them. Learn more or join at: https://grabarlaw.com/the-latest/actinium-shareholder-investigations/. Contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.

WHY: An underlying securities fraud class action complaint alleges that Actinium Pharmaceuticals, Inc. (NYSE: ANTM), through certain of its officers, made materially false and misleading statements that conditioned investors to believe that there was a very high likelihood that the Food and Drug Administration ("FDA") would review and approve Actinium's Biologics License Application ("BLA") for Iomab-B. Specifically, Defendants (1) repeatedly touted the Phase 3 Sierra trial's (the "Sierra Trial") positive Complete Remission ("DCR") data while downplaying the study's failure to generate statistically significant or clinically meaningful Overall Survival data; and (2) misled investors about the importance of the Sierra Trial's poor Overall Survival data by claiming that the FDA had somehow blessed the design of the Sierra Trial such that the lack of statistically significant or clinically meaningful OS data would not be a barrier to approval of the Biologics License Application ("BLA").

WHAT TO DO NOW: Current Actinium shareholders who have held Actinium shares since on or before October 31, 2022, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.

If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/actinium-shareholder-investigations/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085. $ANTM #Actinium

Attorney Advertising Disclaimer

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/246568